Amicus Therapeutics, Inc. is a global biotechnology company focused on discovering, developing and delivering medicines for people living with rare diseases. Its two marketed therapies are Galafold, the first oral monotherapy for people living with Fabry disease who have amenable genetic variants, and Pombiliti + Opfolda, a two-component treatment for adults living with late-onset Pompe disease. As an orally miglustat monotherapy, Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A enzyme in those patients with genetic variants identified as amenable in a Good Laboratory Practice cell-based amenability assay. Pombiliti + Opfolda consists of an engineered rhGAA enzyme, cipaglucosidase alfa-atga, with an optimized carbohydrate structure to enhance cellular uptake, administered intravenously in combination with orally administered miglustat. In addition, clinical studies are ongoing in pediatric patients for both the LOPD and IOPD populations.

Employees

Sector

Biotechnology & Medical Research

More about the company

Market Cap	454.99Cr 391.03Cr 368.11Cr 335.91Cr 627.93Cr 43TCr 630.67Cr 4.36TCr 1.69TCr 22TCr 1.71TCr 1.67TCr 70TCr	P/E 2024	-51.1x	P/E 2025	-162x
Enterprise Value	469.87Cr 403.82Cr 380.15Cr 346.9Cr 648.47Cr 45TCr 651.29Cr 4.5TCr 1.74TCr 23TCr 1.76TCr 1.73TCr 72TCr	EV / Sales 2024	5.69x	EV / Sales 2025	7.18x
Free-Float	99.31%	Yield 2024 *	-	Yield 2025	-

05/05	BioMarin Enters 'Transition Year' as Enzyme Portfolio Expands After Amicus Deal, Morgan Stanley Says	MT
29/04	Amicus Therapeutics, Inc.(NasdaqGM:FOLD) dropped from S&P Global BMI Index	CI
29/04	Amicus Therapeutics, Inc.(NasdaqGM:FOLD) dropped from S&P TMI Index	CI
29/04	Amicus Therapeutics, Inc.(NasdaqGM:FOLD) dropped from S&P Biotechnology Select Industry Index	CI
28/04	Amicus Therapeutics, Inc.(NasdaqGM:FOLD) dropped from Russell 3000E Index	CI
28/04	Amicus Therapeutics, Inc.(NasdaqGM:FOLD) dropped from Russell 3000E Growth Benchmark	CI
28/04	Amicus Therapeutics, Inc.(NasdaqGM:FOLD) dropped from Russell 3000 Growth Benchmark	CI
28/04	Amicus Therapeutics, Inc.(NasdaqGM:FOLD) dropped from Russell 2500 Growth Benchmark	CI
28/04	Amicus Therapeutics, Inc.(NasdaqGM:FOLD) dropped from Russell 2000 Growth Benchmark	CI
28/04	Amicus Therapeutics, Inc.(NasdaqGM:FOLD) dropped from Russell 2500 Growth-Dynamic Index	CI
28/04	Amicus Therapeutics, Inc.(NasdaqGM:FOLD) dropped from Russell 2000 Growth-Dynamic Index	CI
28/04	Amicus Therapeutics, Inc.(NasdaqGM:FOLD) dropped from Russell 2500 Dynamic Index	CI
28/04	Amicus Therapeutics, Inc.(NasdaqGM:FOLD) dropped from Russell 3000E Growth Index	CI

05/05	BioMarin Enters 'Transition Year' as Enzyme Portfolio Expands After Amicus Deal, Morgan Stanley Says	MT
22/01	Jefferies Downgrades Amicus Therapeutics to Hold From Buy, Adjusts Price Target to $14.50 From $16	MT
29/12	Leerink Downgrades Amicus Therapeutics to Market Perform From Outperform, Adjusts Price Target to $14.50 From $17	MT
22/12	TD Cowen Downgrades Amicus Therapeutics to Hold From Buy, Adjusts PT to $14.50 From $20	MT
19/12	Top Midday Gainers	MT

09/03	US Senate Probes FDA Bureaucracy vs. Innovation	AQ
23/02	Amicus Therapeutics: Q4 Earnings Snapshot	AQ
21/02	Amicus Therapeutics Announces Full-Year 2025 Financial Results and Corporate Updates	AQ
03/02	Amicus Therapeutics Presents New Long-term Data for both Galafold® (migalastat) and POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at the 22nd Annual WORLDSymposium™ 2026	AQ
10/01	Amicus Therapeutics : Legend (1)	PU

20/02	BB Biotech bestätigt Gewinn 2025
20/12	Wall Street optimistisch het weekend in
20/12	MÄRKTE USA/Zinssenkungshoffnung stützen Börse - Oracle fest
19/12	MÄRKTE USA/Börsen von Zinssenkungshoffnung gestützt - Oracle fest
19/12	MÄRKTE USA/Positive Stimmung hält - Oracle mit TikTok-Deal fest

Amicus Therapeutics Share Price Nasdaq

Stocks

Biotechnology & Medical Research

Valuation : Amicus Therapeutics

Latest news : Amicus Therapeutics

Last Transcript : Amicus Therapeutics

Analysts' recommendations : Amicus Therapeutics

Press Releases : Amicus Therapeutics

News in other languages : Amicus Therapeutics

Quotes and Performance

Managers and Directors : Amicus Therapeutics

Other Biotechnology & Medical Research

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
AMICUS THERAPEUTICS	+1.57%	+1.65%	-	-	454.99Cr
LONZA GROUP AG	-3.24%	-6.89%	-5.65%	+11.20%	4.8TCr
REVOLUTION MEDICINES, INC.	+0.17%	-1.04%	+405.80%	+546.58%	4.44TCr
IQVIA HOLDINGS INC.	-0.86%	-0.53%	+36.92%	+20.35%	4.27TCr
BEONE MEDICINES AG	-0.14%	-2.13%	+1.31%	+82.21%	4TCr
CELLTRION, INC.	0.00%	-2.61%	+13.09%	+42.33%	3.28TCr
ASCENDIS PHARMA A/S	-3.44%	+0.22%	-	-	1.77TCr
MEDPACE HOLDINGS, INC.	-0.78%	+0.53%	+19.14%	+116.26%	1.65TCr
EUROFINS SCIENTIFIC SE	-0.37%	-0.87%	+10.98%	+30.93%	1.44TCr
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-0.86%	-1.41%	+71.82%	+39.36%	1.34TCr
Average	-0.80%	-0.53%	+69.18%	+111.15%	3TCr
Weighted average by Cap.	-1.00%	-1.10%	+84.31%	+131.92%

	2024	2025
Net sales	53Cr 45Cr 43Cr 39Cr 73Cr 5.03TCr 73Cr 506.26Cr 195.8Cr 2.56TCr 198.3Cr 194.04Cr 8.11TCr	63Cr 55Cr 51Cr 47Cr 88Cr 6.03TCr 88Cr 607.75Cr 235.06Cr 3.07TCr 238.06Cr 232.94Cr 9.74TCr
Net income	-5.61Cr -4.82Cr -4.54Cr -4.14Cr -7.74Cr -533.74Cr -7.78Cr -54Cr -21Cr -271.98Cr -21Cr -21Cr -861.27Cr	-2.71Cr -2.33Cr -2.19Cr -2Cr -3.74Cr -257.9Cr -3.76Cr -26Cr -10Cr -131.42Cr -10Cr -9.96Cr -416.16Cr
Net Debt	19Cr 17Cr 16Cr 14Cr 27Cr 1.84TCr 27Cr 185.62Cr 72Cr 938.98Cr 73Cr 71Cr 2.97TCr	15Cr 13Cr 12Cr 11Cr 21Cr 1.42TCr 21Cr 142.62Cr 55Cr 721.46Cr 56Cr 55Cr 2.28TCr